Brain cancer stock alert -> NASDAQ

New Drug Candidate To Target Most Aggressive Type Of Brain Cancer Received Positive FDA Pre-IND Guidance



cns
Dear Reader,

The NASDAQ stock exchange is abundant with emerging growth biotech stocks, but there is one company that is on our radar that is targeting the most aggressive type of brain cancer that was developed at the largest cancer treatment and research institute in the world.

They recently IPO'd at $4 per share and they are preparing to begin their Phase II clinical trials.

We've put together a detailed report on why we believe it offers investors a unique opportunity in the biotech space.

Click here for more details.







©2019 Trade Stocks. All Rights Reserved.

RISK DISCLAIMER: Before deciding to participate in any investment, you should carefully consider your investment objectives, level of experience and risk tolerance. Most importantly, do not invest money you cannot afford to lose. Trade Stocks is not a registered broker-dealer. Trade Stocks does not give investment advice, endorsement, analysis or recommendations with respect to any securities. Trade Stocks has not taken any steps to verify the adequacy, accuracy or completeness of any information. Neither Trade Stocks nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Trade Stocks does not make investment recommendations and no communication, through this website or in any other medium should be construed as an investment recommendation. Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. Additionally, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.


This is a PAID ADVERTISEMENT provided to customers of StockEarnings. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that StockEarnings Inc. "StockEarnings's" is receiving a fee of over $1000.00 in cash, from an independent third party as compensation for the distribution of this advertisement. StockEarnings's has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment.

Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at http://www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at http://www.sec.gov/consumer as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.

Click Here To Unsubscribe

StockEarnings.com

No comments:

Post a Comment